| Dr Sachin Gupta, MD | |
|
1411 E 31st St, Oakland, CA 94602-1018 | |
| (650) 763-7791 | |
| Not Available |
| Full Name | Dr Sachin Gupta |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 16 Years |
| Location | 1411 E 31st St, Oakland, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215163183 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | A111461 (California) | Secondary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | A111461 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Highland Hospital | Oakland, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alameda Health System | 3779494521 | 504 |
| San Francisco Critical Care Med Group Inc | 1850285602 | 15 |
News Archive
StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.
BioTek Instruments, Inc. affirms their ongoing investment across the North American microplate-based technology market with the expansion of their business in Canada. The dedicated sales and support operation will focus on bringing enhanced applications and technical support throughout the country.
Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient's future risk of heart attack, stroke, or premature death, according to a study led by Icahn School of Medicine at Mount Sinai and published in the March 24 edition of the Journal of the American College of Cardiology.
Today's headlines reflect the continued coverage of President Obama's recess appointment of Dr. Donald Berwick to head CMS as well as other developments related to Medicaid, the health insurance industry and state challenges to the health reform law.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
› Verified 5 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.
BioTek Instruments, Inc. affirms their ongoing investment across the North American microplate-based technology market with the expansion of their business in Canada. The dedicated sales and support operation will focus on bringing enhanced applications and technical support throughout the country.
Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient's future risk of heart attack, stroke, or premature death, according to a study led by Icahn School of Medicine at Mount Sinai and published in the March 24 edition of the Journal of the American College of Cardiology.
Today's headlines reflect the continued coverage of President Obama's recess appointment of Dr. Donald Berwick to head CMS as well as other developments related to Medicaid, the health insurance industry and state challenges to the health reform law.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
› Verified 5 days ago
| Entity Name | Alameda Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740332931 PECOS PAC ID: 3779494521 Enrollment ID: O20031110000764 |
News Archive
StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.
BioTek Instruments, Inc. affirms their ongoing investment across the North American microplate-based technology market with the expansion of their business in Canada. The dedicated sales and support operation will focus on bringing enhanced applications and technical support throughout the country.
Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient's future risk of heart attack, stroke, or premature death, according to a study led by Icahn School of Medicine at Mount Sinai and published in the March 24 edition of the Journal of the American College of Cardiology.
Today's headlines reflect the continued coverage of President Obama's recess appointment of Dr. Donald Berwick to head CMS as well as other developments related to Medicaid, the health insurance industry and state challenges to the health reform law.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
› Verified 5 days ago
| Entity Name | San Francisco Critical Care Med Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215000211 PECOS PAC ID: 1850285602 Enrollment ID: O20040211001214 |
News Archive
StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.
BioTek Instruments, Inc. affirms their ongoing investment across the North American microplate-based technology market with the expansion of their business in Canada. The dedicated sales and support operation will focus on bringing enhanced applications and technical support throughout the country.
Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient's future risk of heart attack, stroke, or premature death, according to a study led by Icahn School of Medicine at Mount Sinai and published in the March 24 edition of the Journal of the American College of Cardiology.
Today's headlines reflect the continued coverage of President Obama's recess appointment of Dr. Donald Berwick to head CMS as well as other developments related to Medicaid, the health insurance industry and state challenges to the health reform law.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
› Verified 5 days ago
| Entity Name | Enloe Medical Center |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1477975613 PECOS PAC ID: 9739092388 Enrollment ID: O20140401001696 |
News Archive
StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.
BioTek Instruments, Inc. affirms their ongoing investment across the North American microplate-based technology market with the expansion of their business in Canada. The dedicated sales and support operation will focus on bringing enhanced applications and technical support throughout the country.
Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient's future risk of heart attack, stroke, or premature death, according to a study led by Icahn School of Medicine at Mount Sinai and published in the March 24 edition of the Journal of the American College of Cardiology.
Today's headlines reflect the continued coverage of President Obama's recess appointment of Dr. Donald Berwick to head CMS as well as other developments related to Medicaid, the health insurance industry and state challenges to the health reform law.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sachin Gupta, MD 163 Elderberry Ln, Brisbane, CA 94005-1414 Ph: (415) 745-5487 | Dr Sachin Gupta, MD 1411 E 31st St, Oakland, CA 94602-1018 Ph: (650) 763-7791 |
News Archive
StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.
BioTek Instruments, Inc. affirms their ongoing investment across the North American microplate-based technology market with the expansion of their business in Canada. The dedicated sales and support operation will focus on bringing enhanced applications and technical support throughout the country.
Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient's future risk of heart attack, stroke, or premature death, according to a study led by Icahn School of Medicine at Mount Sinai and published in the March 24 edition of the Journal of the American College of Cardiology.
Today's headlines reflect the continued coverage of President Obama's recess appointment of Dr. Donald Berwick to head CMS as well as other developments related to Medicaid, the health insurance industry and state challenges to the health reform law.
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia. Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
› Verified 5 days ago
Ms. Samira Yasmeen Ahmed, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1411 E 31st St, Oakland, CA 94602 Phone: 510-437-4800 | |
Jeeven Brah, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 350 Hawthorne Ave, Room 2346, Oakland, CA 94609 Phone: 510-869-6883 | |
Sanya Wadhwa, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Frank H Ogawa Plz Ste 355, Oakland, CA 94612 Phone: 510-444-3297 Fax: 510-444-6421 | |
Michael Uzoma Ohabughiro, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1411 E 31st St Fl 2, Oakland, CA 94602 Phone: 510-437-5039 Fax: 510-535-7313 | |
Lisha Lynne Wilson, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 400 29th St, Ste 501, Oakland, CA 94609 Phone: 510-268-1800 Fax: 510-268-1803 | |
Chee C. Chow, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 275 W Macarthur, Oakland, CA 94611 Phone: 510-752-1000 | |
David M. Bliss, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 1950 Franklin St, Oakland, CA 94612 Phone: 510-987-1000 |